DCT

2:26-cv-03796

ARS Pharma Operations Inc v. Cipla Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-03796, D.N.J., 04/10/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey based on Defendant Cipla USA, Inc. maintaining a regular and established place of business in the district and both defendants allegedly deriving substantial revenue from goods used or consumed within the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of Plaintiffs' neffy® epinephrine nasal spray constitutes an act of patent infringement.
  • Technical Context: The technology relates to pharmaceutical compositions and methods for the intranasal administration of epinephrine, a critical medication for the emergency treatment of severe allergic reactions, including anaphylaxis.
  • Key Procedural History: The lawsuit is a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A), triggered by Defendants' filing of ANDA No. 220606 and their associated Paragraph IV Certification alleging the asserted patents are invalid and/or not infringed. The complaint notes that the asserted patents are also the subject of other pending litigation in the same court against Lupin Inc.

Case Timeline

Date Event
2013-07-25 Priority Date for U.S. Patent Nos. 10,576,156 and 11,173,209
2018-12-21 Priority Date for U.S. Patent Nos. 10,682,414; 11,191,838; 11,717,571; 11,744,895; 11,918,655; and 12,324,838
2020-03-03 U.S. Patent No. 10,576,156 Issued
2020-06-16 U.S. Patent No. 10,682,414 Issued
2021-11-16 U.S. Patent No. 11,173,209 Issued
2021-12-07 U.S. Patent No. 11,191,838 Issued
2023-08-08 U.S. Patent No. 11,717,571 Issued
2023-09-05 U.S. Patent No. 11,744,895 Issued
2024-03-05 U.S. Patent No. 11,918,655 Issued
2025-06-10 U.S. Patent No. 12,324,838 Issued
2026-03-24 Date of Cipla's letter informing Plaintiffs of Paragraph IV Certification filing
2026-03-25 Approximate date Plaintiffs received Cipla's Notice Letter
2026-04-10 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,576,156 - "Compositions for drug administration"

The Invention Explained

  • Problem Addressed: The patent describes the low oral bioavailability of many therapeutic agents, particularly peptides and proteins, which are susceptible to hydrolysis in the gastrointestinal tract and exhibit poor absorption across mucosal membranes, typically requiring administration by injection '156 Patent, col. 2:1-17
  • The Patented Solution: The invention is a therapeutic composition that combines a drug with a specific type of non-toxic surfactant-an alkyl glycoside-to enhance the drug's absorption and bioavailability '156 Patent, col. 3:5-13 This surfactant is described as stabilizing the therapeutic agent and increasing its passage through mucosal barriers without causing irritation, thereby allowing for effective administration via non-invasive routes like nasal spray '156 Patent, abstract '156 Patent, col. 2:26-38
  • Technical Importance: This technology offers a potential alternative to injections for delivering complex drugs, which could improve patient compliance and expand the clinical applications for peptide and protein therapeutics '156 Patent, col. 2:63-67

Key Claims at a Glance

  • The complaint alleges infringement of one or more unspecified claims of the '156 Patent Compl. ¶44 Claim 1, an independent claim, is representative of the patent's composition claims.
  • Essential elements of Claim 1 of the '156 Patent:
    • An intranasal pharmaceutical composition comprising:
    • epinephrine; and
    • between about 0.05% and 0.5% (w/v) of an alkylglycoside;
    • wherein the alkylglycoside is dodecyl-beta-D-maltoside;
    • wherein the composition is an aqueous solution formulated for intranasal delivery;
    • wherein the composition provides systemic absorption of epinephrine; and
    • wherein the composition has a pH of about 2.0 to 5.0.
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 10,682,414 - "Intranasal epinephrine formulations and methods for the treatment of disease"

The Invention Explained

  • Problem Addressed: The patent background identifies a "significant need" for needle-free and non-invasive methods of dosing epinephrine for anaphylaxis treatment '414 Patent, col. 2:10-12 It notes that existing auto-injectors can be cumbersome, require training, and that many patients are reluctant to use them due to a fear of injection '414 Patent, col. 2:20-28
  • The Patented Solution: The invention provides a method of treating anaphylaxis and other conditions by administering an intranasal formulation of epinephrine using a compact unit dose sprayer device '414 Patent, col. 2:42-48 The formulation is designed to provide rapid and reliable dosing that can be administered by an untrained individual '414 Patent, col. 2:38-42
  • Technical Importance: This approach provides a more convenient, discrete, and less intimidating alternative to intramuscular injections for the emergency treatment of life-threatening allergic reactions '414 Patent, col. 2:35-39

Key Claims at a Glance

  • The complaint alleges infringement of one or more unspecified claims of the '414 Patent Compl. ¶50 Claim 1, an independent claim, is representative of the patent's method-of-use claims.
  • Essential elements of Claim 1 of the '414 Patent:
    • A method of treating a type-1 hypersensitivity reaction in a human comprising:
    • intranasally administering a single dose of a nasal spray pharmaceutical formulation;
    • wherein the single dose comprises between 0.1 mg and about 2.4 mg of epinephrine;
    • the formulation also includes one or more other agents as excipients and water;
    • the formulation has a pH between about 3.0 and about 5.0; and
    • the volume of the single administered dose is between 25 µL and 250 µL.
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 11,173,209 - "Compositions for drug administration"

  • Patent Identification: U.S. Patent No. 11,173,209, "Compositions for drug administration", issued November 16, 2021 Compl. ¶23
  • Technology Synopsis: This patent, related to the '156 Patent, describes pharmaceutical compositions containing an alkylglycoside as a surfactant to enhance the bioavailability of a therapeutic agent, such as epinephrine, for administration through mucosal membranes '209 Patent, abstract '209 Patent, col. 2:26-38
  • Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶57
  • Accused Features: The Cipla ANDA Product is accused of infringing the patent Compl. ¶57

U.S. Patent No. 11,191,838 - "Intranasal epinephrine formulations and methods for the treatment of disease"

  • Patent Identification: U.S. Patent No. 11,191,838, "Intranasal epinephrine formulations and methods for the treatment of disease", issued December 7, 2021 Compl. ¶24
  • Technology Synopsis: This patent, related to the '414 Patent, covers intranasal formulations of epinephrine and methods for treating conditions like anaphylaxis. The invention addresses the need for a non-invasive, needle-free alternative to epinephrine auto-injectors '11-838 Patent, abstract '11-838 Patent, col. 2:24-42
  • Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶64
  • Accused Features: The Cipla ANDA Product is accused of infringing the patent Compl. ¶64

U.S. Patent No. 11,717,571 - "Intranasal epinephrine formulations and methods for the treatment of disease"

  • Patent Identification: U.S. Patent No. 11,717,571, "Intranasal epinephrine formulations and methods for the treatment of disease", issued August 8, 2023 Compl. ¶25
  • Technology Synopsis: Continuing the technology of the '414 and '11-838 patents, this patent describes intranasal epinephrine formulations designed for rapid and reliable dosing in emergency situations, such as anaphylaxis '571 Patent, abstract '571 Patent, col. 2:39-48
  • Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶71
  • Accused Features: The Cipla ANDA Product is accused of infringing the patent Compl. ¶71

U.S. Patent No. 11,744,895 - "Intranasal epinephrine formulations and methods for the treatment of disease"

  • Patent Identification: U.S. Patent No. 11,744,895, "Intranasal epinephrine formulations and methods for the treatment of disease", issued September 5, 2023 Compl. ¶26
  • Technology Synopsis: This patent further covers intranasal epinephrine formulations and their use in treating conditions like anaphylaxis, focusing on providing a convenient, needle-free alternative to intramuscular injections '895 Patent, abstract '895 Patent, col. 2:40-49
  • Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶78
  • Accused Features: The Cipla ANDA Product is accused of infringing the patent Compl. ¶78

U.S. Patent No. 11,918,655 - "Intranasal epinephrine formulations and methods for the treatment of disease"

  • Patent Identification: U.S. Patent No. 11,918,655, "Intranasal epinephrine formulations and methods for the treatment of disease", issued March 5, 2024 Compl. ¶27
  • Technology Synopsis: This patent continues to describe intranasal epinephrine formulations and methods for treating diseases, aimed at providing an improved, non-invasive method for dosing epinephrine in emergency situations '655 Patent, abstract '655 Patent, col. 2:38-42
  • Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶85
  • Accused Features: The Cipla ANDA Product is accused of infringing the patent Compl. ¶85

U.S. Patent No. 12,324,838 - "Intranasal epinephrine formulations and methods for the treatment of disease"

  • Patent Identification: U.S. Patent No. 12,324,838, "Intranasal epinephrine formulations and methods for the treatment of disease", issued June 10, 2025 Compl. ¶28
  • Technology Synopsis: This patent also covers intranasal epinephrine formulations and methods for disease treatment, focusing on creating a reliable, needle-free alternative to auto-injectors for conditions like anaphylaxis '12-838 Patent, abstract '12-838 Patent, col. 2:35-39
  • Asserted Claims: The complaint alleges infringement of one or more unspecified claims Compl. ¶92
  • Accused Features: The Cipla ANDA Product is accused of infringing the patent Compl. ¶92

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' proposed generic epinephrine nasal spray, identified as the "Cipla ANDA Product" associated with ANDA No. 220606 Compl. ¶1 Compl. ¶14

Functionality and Market Context

  • The Cipla ANDA Product is a 1 mg/spray and 2 mg/spray epinephrine nasal spray intended for the emergency treatment of type I allergic reactions, including anaphylaxis Compl. ¶1 Compl. ¶31 Compl. ¶34 The complaint alleges that Cipla has represented to the FDA that its product is bioequivalent to Plaintiffs' neffy® brand product Compl. ¶36
  • The filing of the ANDA signifies Cipla's intent to engage in the commercial manufacture, use, and sale of this generic product in the United States upon receiving FDA approval, prior to the expiration of the patents-in-suit Compl. ¶35

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element analysis of infringement for any of the asserted patents, nor does it include or reference any claim charts. The central allegation is that the filing of ANDA No. 220606 constitutes a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶41 The complaint alleges that upon approval, Cipla's manufacture, use, or sale of the Cipla ANDA Product will directly infringe or induce infringement of at least one claim of each of the asserted patents Compl. ¶46 Compl. ¶52 This theory appears to be based on the assertion that the Cipla ANDA Product is a generic equivalent of neffy® and is bioequivalent to it, and that neffy® is covered by the patents-in-suit Compl. ¶31 Compl. ¶36 Compl. ¶43

No probative visual evidence provided in complaint.

  • Identified Points of Contention:
    • Scope Questions: A primary question for the composition claims (e.g., in the '156 Patent) will be whether the specific formulation detailed in Cipla's confidential ANDA falls within the claimed ranges for each component, including the concentration of the "dodecyl-beta-D-maltoside" absorption enhancer and the formulation's pH. For the method claims (e.g., in the '414 Patent), a key question will be whether the proposed label for the Cipla ANDA Product instructs or encourages administration in a manner that meets all steps of the claimed method, such as the "single dose" volume and epinephrine concentration.
    • Technical Questions: A factual question for the court will be to compare the technical specifications of the Cipla ANDA Product with the limitations of the asserted claims. As the complaint lacks any detail about the accused product's formulation, discovery will be required to determine if there is a technical match or mismatch with elements such as the exact chemical composition, concentration of excipients, and pH, as recited in claims like Claim 1 of the '156 Patent.

V. Key Claim Terms for Construction

The complaint does not identify any specific claim terms as being central to the dispute. However, based on the technology and the nature of ANDA litigation, the following terms may become focal points.

  • The Term: "alkylglycoside" (from the '156 patent family)

  • Context and Importance: This term is the core of the novel excipient technology claimed in several patents. Its construction will determine the scope of absorption enhancers covered. Practitioners may focus on this term because Cipla's non-infringement position could argue that its chosen excipient, even if functional, is chemically distinct from the claimed "alkylglycoside" or, more specifically, "dodecyl-beta-D-maltoside."

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification of the '156 Patent discusses "alkyl glycosides" as a class of compounds, mentioning a range of possible alkyl chain lengths (e.g., from about 9 to 24 carbons) and saccharide moieties (e.g., glucose, maltose, sucrose), which may support a construction that is not strictly limited to the exact embodiment in the claim '156 Patent, col. 26:1-14
    • Evidence for a Narrower Interpretation: Claim 1 of the '156 Patent explicitly recites "wherein the alkylglycoside is dodecyl-beta-D-maltoside," which may be argued to limit the scope of "alkylglycoside" in that claim to that specific compound. The abstract also highlights an alkyl chain length of "about 10 to about 16 carbon atoms," which could be used to argue for a narrower range than the full specification might otherwise suggest '156 Patent, abstract '156 Patent, claim 1

  • The Term: "systemic absorption" (from the '156 patent family)

  • Context and Importance: This is a functional limitation required by the composition claims. The definition is critical because infringement requires proving not just what the composition is, but what it does. A dispute could arise over the degree or rate of absorption required to meet this limitation.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent's general description of enhancing bioavailability may support a broad definition where any measurable absorption into the bloodstream that is greater than what would occur without the enhancer meets the limitation '156 Patent, col. 3:5-9
    • Evidence for a Narrower Interpretation: The patent includes figures and data showing significant pharmacokinetic effects, such as Tmax values "substantially less than six hours" and high bioavailability compared to injections '156 Patent, col. 8:1-4 '156 Patent, FIGS. 12-15 A defendant may argue that "systemic absorption" must be interpreted in light of these examples to mean a level of absorption that is therapeutically meaningful and rapid, not merely detectable.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Cipla's future actions will induce infringement of the patents-in-suit Compl. ¶46 Compl. ¶52 This allegation appears to be based on the premise that the labeling for the Cipla ANDA Product will instruct healthcare providers and patients to administer the generic drug in a manner that practices the methods claimed in patents like the '414 Patent Compl. ¶33
  • Willful Infringement: The complaint does not contain an explicit allegation of willful infringement. It includes a prayer for attorneys' fees under 35 U.S.C. § 285, which is reserved for "exceptional cases" Compl. ¶(h) at p. 18

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of formulation identity: does the chemical composition of Cipla's proposed generic product, as detailed in its confidential ANDA, fall within the scope of the composition claims, particularly with respect to the identity and concentration of the claimed "dodecyl-beta-D-maltoside" absorption enhancer and the formulation's pH?
  • A key question of induced infringement will turn on the contents of the proposed product labeling for the Cipla ANDA Product. The court will need to determine if those instructions for use will inevitably lead end-users to perform the patented methods of treatment, such as administering a "single dose" with the claimed volume and epinephrine concentration.
  • A foundational question will be the scope and validity of the claims themselves. Given that this dispute centers on a generic version of an approved drug, the court will likely face arguments concerning whether the asserted patent claims are broad enough to read on Cipla's formulation while also being narrow enough to be valid over the prior art concerning nasal drug delivery and epinephrine formulations.
Loading Complaint